Molecular Classification of Malignant Pleural Mesothelioma: Identification of a Poor Prognosis Subgroup Linked to the Epithelial-to-Mesenchymal Transition

Purpose: Despite research efforts to develop more effective diagnostic and therapeutic approaches, malignant pleural mesothelioma (MPM) prognosis remains poor. The assessment of tumor response to therapy can be improved by a deeper phenotypical classification of the tumor, with emphasis on its clinico-biological heterogeneity. The identification of molecular profiles is a powerful approach to better define MPM subclasses and targeted therapies. Experimental Design: Molecular subclasses were defined by transcriptomic microarray on 38 primary MPM cultures. A three-gene predictor, identified by quantitative reverse transcription PCR, was used to classify an independent series of 108 frozen tumor samples. Gene mutations were determined in BAP1, CDKN2A, CDKN2B, NF2, and TP53. Epithelial-to-mesenchymal transition (EMT) markers were studied at the mRNA and protein levels. Results: Unsupervised hierarchical clustering on transcriptomic data defined two robust MPM subgroups (C1 and C2), closely related to prognosis and partly to histologic subtypes. All sarcomatoid/desmoplastic MPM were included in the C2 subgroup. Epithelioid MPM were found in both subgroups, with a worse survival prognosis in the C2 subgroup. This classification and its association with histologic subtypes and survival were validated in our independent series using the three-gene predictor. Similar subgroups were found after classification of other MPM series from transcriptomic public datasets. C1 subgroup exhibited more frequent BAP1 alterations. Pathway analysis revealed that EMT was differentially regulated between MPM subgroups. C2 subgroup is characterized by a mesenchymal phenotype. Conclusions: A robust classification of MPM that defines two subgroups of epithelioid MPM, characterized by different molecular profiles, gene alterations, and survival outcomes, was established. Clin Cancer Res; 20(5); 1323–34. ©2014 AACR.

[1]  C. Sander,et al.  The nuclear deubiquitinase BAP 1 is commonly inactivated by somatic mutations and 3 p 21 . 1 losses in malignant pleural mesothelioma , 2015 .

[2]  Chuong D. Hoang,et al.  miR-1 induces growth arrest and apoptosis in malignant mesothelioma. , 2013, Chest.

[3]  A. Gown,et al.  Guidelines for pathologic diagnosis of malignant mesothelioma: 2012 update of the consensus statement from the International Mesothelioma Interest Group. , 2013, Archives of pathology & laboratory medicine.

[4]  F. Galateau-Sallé,et al.  Differential mutation profiles and similar intronic TP53 polymorphisms in asbestos-related lung cancer and pleural mesothelioma. , 2013, Mutagenesis.

[5]  Samy Lamouille,et al.  Regulation of epithelial-mesenchymal and mesenchymal-epithelial transitions by microRNAs. , 2013, Current opinion in cell biology.

[6]  P. Kapur,et al.  Effects on survival of BAP1 and PBRM1 mutations in sporadic clear-cell renal-cell carcinoma: a retrospective analysis with independent validation. , 2013, The Lancet. Oncology.

[7]  Y. Soini,et al.  Expression of snail, twist, and Zeb1 in malignant mesothelioma , 2013, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.

[8]  M. Ladanyi,et al.  Clinical Characteristics of Patients with Malignant Pleural Mesothelioma Harboring Somatic BAP1 Mutations , 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[9]  A. Hata,et al.  Targeting the TGFβ signalling pathway in disease , 2012, Nature Reviews Drug Discovery.

[10]  S. Armato,et al.  Multicenter, double-blind, placebo-controlled, randomized phase II trial of gemcitabine/cisplatin plus bevacizumab or placebo in patients with malignant mesothelioma. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  N. Le Stang,et al.  Plasma Cell Membrane Localization of c-MET Predicts Longer Survival in Patients with Malignant Mesothelioma: A Series of 157 Cases from the MESOPATH Group , 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[12]  F. Galateau-Sallé,et al.  Molecular changes in mesothelioma with an impact on prognosis and treatment. , 2012, Archives of pathology & laboratory medicine.

[13]  P. Betta,et al.  Immunohistochemistry and molecular diagnostics of pleural malignant mesothelioma. , 2012, Archives of pathology & laboratory medicine.

[14]  M. Fassan,et al.  Epithelial–mesenchymal transition in malignant mesothelioma , 2012, Modern Pathology.

[15]  Y. Hayashizaki,et al.  LRRN4 and UPK3B Are Markers of Primary Mesothelial Cells , 2011, PloS one.

[16]  N. Cox,et al.  Germline BAP1 mutations predispose to malignant mesothelioma , 2011, Nature Genetics.

[17]  C. Sander,et al.  The nuclear deubiquitinase BAP1 is commonly inactivated by somatic mutations and 3p21.1 losses in malignant pleural mesothelioma , 2011, Nature Genetics.

[18]  J. Sørensen,et al.  Review on clinical trials of targeted treatments in malignant mesothelioma , 2011, Cancer Chemotherapy and Pharmacology.

[19]  M. Jaurand,et al.  Role of Mutagenicity in Asbestos Fiber-Induced Carcinogenicity and Other Diseases , 2011, Journal of toxicology and environmental health. Part B, Critical reviews.

[20]  F. Barlesi,et al.  Targeted therapies in malignant pleural mesothelioma: a review of clinical studies , 2011, Anti-cancer drugs.

[21]  A. Scherpereel,et al.  Identification of novel markers for the diagnosis of malignant pleural mesothelioma. , 2011, The American journal of pathology.

[22]  F. Galateau-Sallé,et al.  Syntenic relationships between genomic profiles of fiber-induced murine and human malignant mesothelioma. , 2011, The American journal of pathology.

[23]  Michael K. Wendt,et al.  Deconstructing the mechanisms and consequences of TGF-β-induced EMT during cancer progression , 2011, Cell and Tissue Research.

[24]  A. Bowcock,et al.  Frequent Mutation of BAP1 in Metastasizing Uveal Melanomas , 2010, Science.

[25]  Kakajan Komurov,et al.  Core epithelial-to-mesenchymal transition interactome gene-expression signature is associated with claudin-low and metaplastic breast cancer subtypes , 2010, Proceedings of the National Academy of Sciences.

[26]  A. Scherpereel,et al.  Treatment of malignant pleural mesothelioma: current status and future directions. , 2010, Monaldi archives for chest disease = Archivio Monaldi per le malattie del torace.

[27]  H. Moch,et al.  Prognostic significance of epithelial-mesenchymal transition in malignant pleural mesothelioma. , 2010, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

[28]  Jessica Zucman-Rossi,et al.  p16INK4A inactivation mechanisms in non-small-cell lung cancer patients occupationally exposed to asbestos. , 2010, Lung cancer.

[29]  M. Toyota,et al.  Epigenetic profiles distinguish malignant pleural mesothelioma from lung adenocarcinoma. , 2009, Cancer research.

[30]  A. Gown,et al.  Guidelines for pathologic diagnosis of malignant mesothelioma: a consensus statement from the International Mesothelioma Interest Group. , 2009, Archives of pathology & laboratory medicine.

[31]  F. Galateau-Sallé,et al.  Guidelines of the European Respiratory Society and the European Society of Thoracic Surgeons for the management of malignant pleural mesothelioma , 2009, European Respiratory Journal.

[32]  A. Nicholson,et al.  CDKN2A, NF2, and JUN are dysregulated among other genes by miRNAs in malignant mesothelioma—A miRNA microarray analysis , 2009, Genes, chromosomes & cancer.

[33]  E. Neilson,et al.  Biomarkers for epithelial-mesenchymal transitions. , 2009, The Journal of clinical investigation.

[34]  G. Gordon,et al.  Four-gene expression ratio test for survival in patients undergoing surgery for mesothelioma. , 2009, Journal of the National Cancer Institute.

[35]  B. Christensen,et al.  Epigenetic profiles distinguish pleural mesothelioma from normal pleura and predict lung asbestos burden and clinical outcome. , 2009, Cancer research.

[36]  Yu Wei,et al.  Hepatic stem-like phenotype and interplay of Wnt/beta-catenin and Myc signaling in aggressive childhood liver cancer. , 2008, Cancer cell.

[37]  A. Nicholson,et al.  Gene copy number analysis in malignant pleural mesothelioma using oligonucleotide array CGH , 2007, Cytogenetic and Genome Research.

[38]  Qi Liu,et al.  Improving gene set analysis of microarray data by SAM-GS , 2007, BMC Bioinformatics.

[39]  Peter Bühlmann,et al.  Analyzing gene expression data in terms of gene sets: methodological issues , 2007, Bioinform..

[40]  H. Tagawa,et al.  Genomic profiling of malignant pleural mesothelioma with array‐based comparative genomic hybridization shows frequent non‐random chromosomal alteration regions including JUN amplification on 1p32 , 2007, Cancer science.

[41]  G. Serio,et al.  Cytogenetic and molecular genetic changes in malignant mesothelioma. , 2006, Cancer genetics and cytogenetics.

[42]  A. Olshen,et al.  Global gene expression profiling of pleural mesotheliomas: overexpression of aurora kinases and P16/CDKN2A deletion as prognostic factors and critical evaluation of microarray-based prognostic prediction. , 2006, Cancer research.

[43]  J. Thiery,et al.  Complex networks orchestrate epithelial–mesenchymal transitions , 2006, Nature Reviews Molecular Cell Biology.

[44]  Jiri Zavadil,et al.  TGF-β and epithelial-to-mesenchymal transitions , 2005, Oncogene.

[45]  R. Jensen,et al.  Validation of Genomics-Based Prognostic Tests in Malignant Pleural Mesothelioma , 2005, Clinical Cancer Research.

[46]  David J Sugarbaker,et al.  Tumorigenesis and Neoplastic Progression Identification of Novel Candidate Oncogenes and Tumor Suppressors in Malignant Pleural Mesothelioma Using Large-Scale Transcriptional Profiling , 2005 .

[47]  A. Brody,et al.  Pathogenesis of pleural fibrosis , 2004, Respirology.

[48]  Chuong D. Hoang,et al.  Gene expression profiling identifies matriptase overexpression in malignant mesothelioma. , 2004, Chest.

[49]  Sorin Draghici,et al.  Gene Expression Profiles Predict Survival and Progression of Pleural Mesothelioma , 2004, Clinical Cancer Research.

[50]  Jelle J. Goeman,et al.  A global test for groups of genes: testing association with a clinical outcome , 2004, Bioinform..

[51]  J. Blumenstock,et al.  Using gene expression ratios to predict outcome among patients with mesothelioma. , 2003, Journal of the National Cancer Institute.

[52]  T. Speed,et al.  Summaries of Affymetrix GeneChip probe level data. , 2003, Nucleic acids research.

[53]  P. Janne.  Chemotherapy for malignant pleural mesothelioma. , 2003, Clinical lung cancer.

[54]  B. Addis,et al.  Immunohistochemistry in the distinction between malignant mesothelioma and pulmonary adenocarcinoma: a critical evaluation of new antibodies , 2002, Journal of clinical pathology.

[55]  R. Tibshirani,et al.  Empirical bayes methods and false discovery rates for microarrays , 2002, Genetic epidemiology.

[56]  R. Tibshirani,et al.  Diagnosis of multiple cancer types by shrunken centroids of gene expression , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[57]  David B. Holiday,et al.  Regulation of fibrin deposition by malignant mesothelioma. , 1995, The American journal of pathology.

[58]  M. Jaurand,et al.  Immunocytochemical characterization of cell lines from human malignant mesothelioma: characterization of human mesothelioma cell lines by immunocytochemistry with a panel of monoclonal antibodies. , 1994, Human pathology.

[59]  M. Jaurand,et al.  in vitro effects of recombinant human interferon gamma on human mesothelioma cell lines , 1993, International journal of cancer.